Market research
MEDP Medpace Holdings Inc
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 17B
- P/E ratio
- 36.49
- Analyst target
- 581.8333
- Dividend yield
- Not available
- Beta
- 1.15
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- ISIN
- US58506Q1094
- Market cap
- 17B
- P/E ratio
- 36.49
- Analyst target
- 581.8333
- Dividend yield
- Not available
- Beta
- 1.15
About
About Medpace Holdings Inc
Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, Asia, South America, Africa, and Australia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. In addition, the company offers bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. Medpace Holdings, Inc. was founded in 1992 and is based in Cincinnati, Ohio.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the MEDP discussion.
5 years, 4 months ago
Medpace Holdings, Inc is currently in a long term uptrend where the price is trading 19.0% above its 200 day moving average.
From a valuation standpoint, the stock is 99.5% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 6.9.
Medpace Holdings, Inc's total revenue rose by 13.0% to $260M since the same quarter in the previous year.
Its net income has increased by 70.6% to $51M since the same quarter in the previous year.
Finally, its free cash flow grew by 90.9% to $98M since the same quarter in the previous year.
Based on the above factors, Medpace Holdings, Inc gets an overall score of 5/5.